1. Home
  2. HWH vs IMRN Comparison

HWH vs IMRN Comparison

Compare HWH & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.68

Market Cap

9.8M

Sector

Health Care

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.16

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
IMRN
Founded
2021
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8M
9.6M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
HWH
IMRN
Price
$1.68
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
743.1K
153.7K
Earning Date
05-14-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
47.37
N/A
EPS
N/A
N/A
Revenue
$866,926.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.68
52 Week High
$7.77
$2.38

Technical Indicators

Market Signals
Indicator
HWH
IMRN
Relative Strength Index (RSI) 75.77 52.58
Support Level $1.00 $0.72
Resistance Level $1.85 $1.24
Average True Range (ATR) 0.22 0.18
MACD 0.08 -0.02
Stochastic Oscillator 42.50 27.86

Price Performance

Historical Comparison
HWH
IMRN

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: